STOCK TITAN

Moolec Science to Host Second Quarter Fiscal Year 2024 Business Update Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Moolec Science SA (NASDAQ:MLEC) announced the release of its Business Update for the Second Quarter Fiscal Year 2024. The live Conference Call with key executives will take place on March 13, 2024, followed by a Q&A session and a presentation. Investors can access the webinar and presentation via the company's Investor Relations website.
Positive
  • None.
Negative
  • None.

LUXEMBOURG / ACCESSWIRE / March 6, 2024 / Moolec Science SA (NASDAQ:MLEC) ("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today that it will release its Business Update for the Second Quarter Fiscal Year 2024 on Wednesday, March 13, 2024, before the market opens.

logo
logo



Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra will host a live Conference Call on Wednesday, March 13, 2024, at 08:30 am ET. Henk Hoogenkamp, Chief Product Officer, will join the subsequent question-and-answer session to be held immediately after the Business Update remarks.

The Conference Call will be accompanied by a presentation, which can be viewed during the webcast. A replay and the pdf version of the presentation will be available approximately two hours after the conclusion of the live event via the company's Investor Relations website.

Connection Details:

About Moolec Science SA

Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food. The Company's mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal-based food, for good and for all. Moolec's technological approach aims to have the cost structure of plant-based solutions with the organoleptic properties and functionality of animal-based ones. Moolec's technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company's product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like soybean, pea, and safflower. Moolec has a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology and a self-owned industrial and commercial R&D center (plant-based ingredient capability that includes a state-of-the-art soybean processing facility with 10,000 tons per year of installed capacity fully operational). The Company is run by a diverse team of Ph.Ds and Food Insiders, and operates in the United States, Europe, and South America.

Forward-Looking Statements

This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Contacts:

Contact Information

Catalina Jones
Chief of Staff & Sustainability
comms@moolecscience.com

Investor Relations
ir@moolecscience.com

Michael Bowen
ICR, LLC
moolecir@icrinc.com

Related Files

Moolec Science Presents First Quarter Fiscal Year 2024 Business Update

SOURCE: Moolec Science

.

View the original press release on newswire.com.

FAQ

When will Moolec Science release its Business Update for the Second Quarter Fiscal Year 2024?

Moolec Science will release its Business Update for the Second Quarter Fiscal Year 2024 on Wednesday, March 13, 2024, before the market opens.

Who will host the live Conference Call on March 13, 2024?

Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra will host the live Conference Call on March 13, 2024, at 08:30 am ET.

Who will join the question-and-answer session after the Business Update remarks?

Henk Hoogenkamp, Chief Product Officer, will join the question-and-answer session after the Business Update remarks.

How can investors access the presentation and webinar?

Investors can access the presentation and webinar via the company's Investor Relations website. A replay and pdf version of the presentation will be available after the live event.

Moolec Science SA Ordinary Shares

NASDAQ:MLEC

MLEC Rankings

MLEC Latest News

MLEC Stock Data

31.84M
38.44M
89.17%
0.22%
0.36%
Biotechnology
Healthcare
Link
United States of America
Luxembourg